- Push-out Score determined
- After less than three years in the position
- Praise and thanks for Hoeiland
- Kelly Martin taking over
- Hoeiland said 125 words
(exechange) — Waltham, Massachusetts, April 28, 2020 — Jesper Hoeiland, chief executive of Radius, leaves. As announced by Radius Health Inc. in a news release and in a regulatory filing published on Tuesday, April 28, 2020, Jesper Hoeiland leaves his post as chief executive officer at the biopharmaceutical company after less than three years in the role, effective immediately.
The announcement of Jesper Hoeiland’s move comes two months after Owen Hughes took over as Chairman of Radius Health, Inc.
Jesper Hoeiland’s duties as CEO will be taken over by G. Kelly Martin, a former Chief Executive Officer of Elan Pharmaceuticals.
The fact that Jesper Hoeiland’s successor is brought in from outside suggests that the board may seek to stimulate change with fresh ideas and new initiatives.
“To return, after many years abroad, to his home country of Denmark”
Jesper Hoeiland’s departure from the CEO post is explained as follows. Radius said: “Jesper Hoeiland will step down as President and Chief Executive Officer to return, after many years abroad, to his home country of Denmark.”
Precise information regarding Jesper Hoeiland’s future plans was not immediately available.
Radius said: “Mr. Martin succeeds Jesper Hoeiland as President and Chief Executive Officer of the Company effective as of April 28, 2020. Mr. Hoeiland resigned as a director of the Company effective as of April 28, 2020.”
Share price decline
The announcement follows a decline in Radius Health Inc.’s share price of 62% since July 2017.
Chaired by Owen Hughes
Radius Health Inc. is chaired by Owen Hughes.
Owen Hughes has served on the Company’s Board of Directors since April 2013 and as Chairman of the Company’s Board of Directors since March 2020. He has served as the Chief Executive Officer of Cullinan Oncology, LLC and an Executive Partner at MPM Capital since October 2017.
In the position of CEO since 2017
Jesper Hoeiland became CEO of the Company in 2017.
In order to assist with the transition, Jesper Hoeiland has agreed to serve as a Senior Advisor to the Company.
Jesper Hoeiland has served as the Company’s President and Chief Executive Officer and as a member of the Company’s Board since July 2017.
Prior to joining Radius, Hoeiland served as President/Executive Vice President of Novo Nordisk, Inc. USA, the US affiliate of Novo Nordisk A/S (“Novo Nordisk”), a global healthcare company focused on diabetes and other serious chronic conditions.
After joining Novo Nordisk in 1987, Hoeiland held multiple global roles of increasing responsibility, including leading its International Operations, which spanned 150 countries.
Hoeiland has 30 years of experience in the biopharmaceutical industry across numerous senior leadership roles, geographies and therapeutic areas.
He possesses extensive knowledge about the areas of endocrinology, biopharmaceuticals and women’s health, as well as unique insights about U.S. market access.
Hoeiland is a member of the board of directors of LEO Pharma A/S, a pharmaceutical company, and Concert Pharmaceuticals, Inc., a biopharmaceutical company.
Hoeiland received his B.Sc. in Economics and M.Sc. in Management from Copenhagen Business School in Denmark.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding the management change on a scale of 0 to 10.
exechange reached out to Radius and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 18.2020 ($).